Knockdown of NF-κB1 by shRNA Inhibits the Growth of Renal Cell Carcinoma In Vitro and In Vivo

Renal cell carcinoma (RCC) accounts for approximately 2%–3% of human malignancies and is the most aggressive among urologic tumors. Biological heterogeneity, drug resistance, and chemotherapy side effects are the biggest obstacles to the effective treatment of RCC. The NF-κB transcription factor is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikegami, Amanda, Teixeira, Luiz Felipe S., Braga, Marina S., Dias, Matheus Henrique Dos S., Lopes, Eduardo C., Bellini, Maria Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844753/
https://www.ncbi.nlm.nih.gov/pubmed/29212573
http://dx.doi.org/10.3727/096504017X15120379906339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844753/
https://www.ncbi.nlm.nih.gov/pubmed/29212573
http://dx.doi.org/10.3727/096504017X15120379906339

Ejemplares similares